An important subgroup of patients experience breakthrough disease on glatiramer acetate or IFNβ within 2 years of treatment initiation.
Patenting growth is significantly higher in cities and technologies where breakthrough inventions occur after 1984 relative to peer locations that do not experience breakthrough inventions.
Up to 30% of patients treated with antiepileptics continue to experience breakthrough seizures and often present to an emergency department [22, 23].
However, patients do not always receive optimal drug therapy and approximately 50 60% of patients with epilepsy experience breakthrough seizures during the course of a year, some of whom will require a prescription for rescue medication [2].
While second-line therapies are more likely to be associated with rare but serious adverse effects, our data provide strong evidence for switching to such treatments when patients experience breakthrough disease on first-line agents.
Also, IFNβ treatment is not always effective, as about 30%to50%0% of patients experience breakthrough disease.
Although newer long-acting antihistamine preparations permit once-daily dosing, many patients with seasonal allergic rhinitis (SAR) experience breakthrough symptoms and a diminution of clinical potency at the end of the dosing interval.
You may experience breakthrough bleeding or 'spotting'spotting
You may experience breakthrough bleeding for a few weeks if this is your first time using hormonal birth control.
20% of people experience breakthrough occurrences early in this treatment.[5] These breakthroughs, while important, do not mean the regimen should discontinue.
